The website of the Clinical Services Journal

Diabetes drug may help prevent recurrent miscarriage

An NIHR-supported study has found that an existing diabetes drug can be used to optimise the lining of the womb and reduce the risk of miscarriage in women who have already experienced pregnancy loss.

There are very few effective treatments for recurrent miscarriage. If successful, this would be the first drug which specifically at the lining of the womb to prevent miscarriage. Recurrent miscarriage is defined as the loss of two or more consecutive pregnancies, with additional miscarriages decreasing the likelihood of a successful pregnancy.

Previous research revealed a lack of stem cells in the womb lining in women with recurrent miscarriage. Stem cells have been shown to improve renewal of the womb lining and reduce inflammation in early pregnancy.

Researchers at supported by the NIHR Coventry and Warwickshire Clinical Research Facility wanted to find out if a drug designed to tackle diabetes - Sitagliptin - could be re- purposed as the first treatment to prevent miscarriage by increasing the number of stem cells.

In a small clinical trial, 38 women aged 18 to 42 who had experienced a large number of recurrent miscarriages (average five) were given either an oral course of sitagliptin or a placebo for three menstrual cycles. Biopsies of the womb were taken at the start of the treatment and afterwards, to determine the number of stem cells present before and after the course.

The researchers found an average increase in stem cell count of 68% in those women who took the full course of sitagliptin. This compares to no significant increase in those in the control group received an identical placebo pill.

They also saw a 50% decrease in the number of ‘stressed’ cells present in the lining of the womb. There were minimal side effects for the participants.

Although this research was specifically designed to test whether sitagliptin could increase the presence of stem cells in the womb, follow-up of participants found that there were no further losses of normal pregnancies in those who took the drug.

These early results now need to be further tested in a large-scale clinical trial.

 

Upcoming Events

Central Sterilising Club - Annual Scientific Meeting 2024

Crowne Plaza at Gerrard’s Cross
15th April 2024 – 16th April 2024

DECON UK 2024

National Conference Centre, Birmingham
17th April 2024

Infection Prevention & Control

National Conference Centre, Birmingham
23rd - 24th April 2024

Theatres & Decontamination Conference 2024

Coventry Building Society Arena
16th May 2024

The AfPP Roadshow - Birmingham

Millennium Point, Birmingham
18th May 2024

The AfPP Roadshow - Exeter

University of Exeter
22nd June 2024

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Upcoming Events

Central Sterilising Club - Annual Scientific Meeting 2024

Crowne Plaza at Gerrard’s Cross
15th April 2024 – 16th April 2024

DECON UK 2024

National Conference Centre, Birmingham
17th April 2024

Infection Prevention & Control

National Conference Centre, Birmingham
23rd - 24th April 2024

Theatres & Decontamination Conference 2024

Coventry Building Society Arena
16th May 2024

The AfPP Roadshow - Birmingham

Millennium Point, Birmingham
18th May 2024

The AfPP Roadshow - Exeter

University of Exeter
22nd June 2024

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025